Cecile Geuijen

Company: Merus

Job title: Chief Scientific Officer & Vice President - Oncology

Seminars:

Zenocutuzumab, a HER2×HER3 Biclonics® Antibody that can Overcome HER3 Mediated NRG1 Signaling in Tumor Cells by Docking on HER2 12:30 pm

• Understanding the status of HER2 and NRG1 fusions • Understanding how Merus are overcoming resistance & leveraging inhibition of signaling • Uncovering the latest data and future directionsRead more

day: Day Two

Panel Discussion: The HER2 Expression Levels Debate: HER2 High vs HER2 Low 11:30 am

• Progress towards an improved standard of HER2 expression definition • Exploring the IHC & FISH standardization and improvement • Understanding different requirements for expression measurement for various indications • How does HER2 expression compare across indications? • How does that compare for a therapeutic in terms of defining illegibility criteria? • How to define…Read more

day: Day One